LobbyingScipher Medicine lobbying by quarter
Scipher Medicine's latest lobbying report covers Q3 2024, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Medicare/Medicaid and Health Issues.
Scipher Medicine
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $211.3K | 3 |
| Q1 2023 | $90K | 2 |
| Q2 2023 | $110K | 2 |
| Q3 2023 | $90K | 2 |
| Q4 2023 | $20K | 2 |
| Q1 2024 | $30K | 2 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $0 | 0 |
| Q1 2026 | $0 | 0 |
| Q2 2026 | $0 | 0 |
| Q3 2026 | $0 | 0 |
By issue
- Medicare and Medicaid$285K · 11 reports
- Health issues$266.3K · 7 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES9 reports
- SENATE9 reports
- Health & Human Services, Dept of (HHS)7 reports
- Centers For Medicare and Medicaid Services (CMS)2 reports
- White House Office1 reports
Firms it paid
| Firm | ||
|---|---|---|
| FGS Global | $190K | 5 quarters |
| Holland & Knight | $190K | 8 quarters |
| In-houseScipher Medicine | $110K | 1 quarters |
| MR. Matthew R. Simmons | $61.3K | 1 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 24/10/09for Q3 2024 | Holland & Knight | Under $5,000 |
| 24/07/19for Q2 2024 | Holland & Knight | Under $5,000 |
| 24/04/22for Q1 2024 | FGS Global | $20K |
| 24/04/14for Q1 2024 | Holland & Knight | $10K |
| 24/02/12for Q4 2022 | MR. Matthew R. Simmons | $61.3K |
| 24/02/12for Q4 2022 | MR. Matthew R. Simmons | Under $5,000 |
| 24/01/18for Q4 2023 | FGS Global | $20K |
| 24/01/13for Q4 2023 | Holland & Knight | Under $5,000 |
| 23/10/19for Q3 2023 | FGS Global | $60K |
| 23/10/13for Q3 2023 | Holland & Knight | $30K |
| 23/08/30for Q4 2022 | In-house | $110K |
| 23/07/19for Q2 2023 | FGS Global | $60K |
| 23/07/12for Q2 2023 | Holland & Knight | $50K |
| 23/04/19for Q1 2023 | FGS Global | $30K |
| 23/04/12for Q1 2023 | Holland & Knight | $60K |
| 23/02/10for Q1 2023 | FGS Global | Under $5,000 |
| 23/01/18for Q4 2022 | Holland & Knight | $40K |